10th MASH Drug Development Summit 2026

When:
Tuesday, Sep 15, 2026 8:00a -
Thursday, Sep 17, 2026 4:00p

Where:
The Colonnade
120 Huntington Avenue
Boston, Massachusetts 02116

EventScheduled OfflineEventAttendanceMode

Admission:
$2699.00 - $5297.00

Hosted by:
...
evvnt.com Account #11193

Categories:
Lectures & Conferences

Event website:
https://go.evvnt.com/3682341-0?pid=5248

MASH drug development is entering a pivotal new phase. As pharmaceutical and biotechnology companies advance differentiated therapies capable of delivering meaningful fibrosis improvement and long-term clinical benefit, growing investment in FGF-21 analogs, combination strategies, non-invasive biomarkers and AI-enabled pathology tools is transforming how therapies are discovered, developed and evaluated.


The 10th MASH Drug Development Summit is the industry's premier forum dedicated exclusively to advancing MASH therapeutics from discovery through clinical development. Bringing together senior leaders across discovery, translational science, clinical development, biomarkers and regulatory strategy, the meeting is designed to tackle the most pressing scientific and development challenges facing the field today.


Across three days of dedicated content, attendees will explore how to improve translational confidence through human-relevant preclinical models, leverage non-invasive biomarkers and AI-enabled pathology to strengthen patient stratification, and advance differentiated therapeutic strategies capable of addressing disease heterogeneity and advanced fibrosis populations.


Hear from experts representing Takeda, Pfizer, AstraZeneca, Madrigal Pharmaceuticals, Akero Therapeutics, Rivus Pharmaceuticals, Corcept Therapeutics, Cellarity, Insitro, Salubris Biotherapeutics, Harvard Medical School and more, as they share the latest approaches shaping the future of MASH drug development.


Join 70+ senior discovery, translational, clinical and regulatory leaders to benchmark strategies, build valuable partnerships and gain practical insights that will help accelerate the development of efficacious therapies for patients living with MASH.


URLs:

Tickets: https://go.evvnt.com/3682341-2?pid=5248

Brochure: https://go.evvnt.com/3682341-3?pid=5248


Prices:

Conference Only - Drug Developer: USD 3099.00,

Conference + Pre-Conference Focus Day - Drug Developer: USD 4397.00,

Conference Only - Academic: USD 2699.00,

Conference + Pre-Conference Focus Day - Academic: USD 3797.00,

Conference Only - Service Provider: USD 3799.00,

Conference + Pre-Conference Focus Day - Service Provider: USD 5297.00


Speakers: Doreen Chan Associate Director, Clinical Research Akero Therapeutics, Marc Thibonnier Founder and President AptamiR Therapeutics, Alok Pachori Medical Director, Global Clinical Development, Late Stage Cardiovascular, Renal and Metabolism AstraZeneca, Yury Popov Associate Professor of Medicine and Director, Liver Fibrosis Research Beth Israel Deaconess Medical Center, Ornella Barrandon Senior Director Cellarity, Robert Beardsley Chief Executive Officer Cirius Therapeutics, Rafael Mayoral Monibas Director, Translational Science, Metabolism Corcept Therapeutics Corcept Therapeutics, Patricia Grebenstein Scientific Researcher and Project Manager Foundation for the National Institutes of Health, Patricia Mendez Clinical Development Lead MASH and Clinical Development Hepatology GlaxoSmithKline, Selma Boulenouar Faculty Harvard Medical School and Mass General Brigham, Santhosh Satapati Senior Director, Metabolic Diseases Insitro, Rebecca Taub Founder, Director and Senior Scientific and Medical Advisor Madrigal Pharmaceuticals, Suneil Hosmane Vice President, Diagnostic Strategy Madrigal Pharmaceuticals, Susana Rios International Medical Director Novo Nordisk, Dimitar Tonev Medical Director Ochre Bio, Kevin Hart Scientific Director and Associate Research Fellow Pfizer, Stefanie Mason Vice President, Head of Clinical Development Rivus Pharmaceuticals, Jijun Dong Chief Scientific Officer Salubris Therapeutics, Amy Curley Vice President, Discovery Biology Sepia Therapeutics, Jen-Chieh (Jay) Chuang Global Program Lead and Translational Medicine, Biomarker Lead, Liver diseases Takeda, Becca Senter Chief Scientific Officer Vertero Therapeutics, Keith Murphy CEO and Founder Viscient Biosciences

Share this event

Add to:

Reddit
09/15/2026 08:00:00 09/17/2026 16:00:00 America/New_York 10th MASH Drug Development Summit 2026 <p>MASH drug development is entering a pivotal new phase. As pharmaceutical and biotechnology companies advance differentiated therapies capable of delivering meaningful fibrosis improvement and lo...

https://www.thebostoncalendar.com/events/10th-mash-drug-development-summit-2026 The Colonnade, Boston, Massachusetts 02116 false MM/DD/YYYY

Sponsored events